Market research reports, consulting: Global Market Insights Inc.
We use cookies to enhance user experience. (Privacy Policy)

Myelodysplastic Syndrome Drugs Market Size

Report ID: GMI10852
   |
Published Date: August 2024
 | 
Report Format: PDF

Download free sample

Myelodysplastic Syndrome Drugs Market Size

Myelodysplastic Syndrome Drugs Market size was valued at USD 2.8 billion in 2023 and is estimated to grow at 8% CAGR from 2024 to 2032. The market is experiencing dynamic growth driven by the increasing incidence of MDS, particularly among the aging population, this has risen the demand for effective treatments.

 

Myelodysplastic Syndrome Drugs Market

For instance, according to the American Cancer Society, approximately 10,000 new cases of MDS are diagnosed annually in the U.S. alone, with a higher incidence in individuals over 60 years old. As a result, the adoption of myelodysplastic syndrome (MDS) drugs is increasing. Moreover, the rise in technological advancement in diagnostic techniques have improved early detection of MDS, which can lead to earlier and more effective treatment, thus increasing the demand for MDS drugs. Furthermore, strategic collaborations and partnerships among biotech firms and research institutions are accelerating the development of new therapies, thereby contributing the market growth.

 

MDS drugs refer to the pharmaceutical treatments used to manage and treat myelodysplastic syndromes (MDS), which are a group of disorders caused by poorly formed or dysfunctional blood cells. MDS affects the bone marrow's ability to produce healthy blood cells, leading to problems like anemia, infections, and bleeding. This market includes a wide range of therapeutic agents such as hypomethylating agents, immunomodulatory drugs, anti-anemics drugs etc.

 

Authors: Mariam Faizullabhoy, Gauri Wani
Frequently Asked Question(FAQ) :
Who are the key leaders in the myelodysplastic syndrome drugs industry?
Otsuka America Pharmaceutical, Inc., Pfizer, Inc., Sandoz, Shilpa Medicare Limited, Sun Pharmaceutical Industries, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd, are some of the major myelodysplastic syndrome (MDS) drugs companies worldwide.
How big is the myelodysplastic syndrome drugs industry?
Why is the demand for hypomethylating myelodysplastic syndrome drugs growing?
What is the size of the North America myelodysplastic syndrome drugs market?

Report Content

Chapter 1   Methodology & Scope

1.1    Market scope & definitions

1.2    Research design

1.2.1    Research approach

1.2.2    Data collection methods

1.3    Base estimates & calculations

1.3.1    Base year calculation

1.3.2    Key trends for market estimation

1.4    Forecast model

1.5    Primary research and validation

1.5.1    Primary sources

1.5.2    Data mining sources

Chapter 2   Executive Summary

2.1    Industry 3600 synopsis

Chapter 3   Industry Insights

3.1    Industry ecosystem analysis

3.2    Industry impact forces

3.2.1    Growth drivers

3.2.1.1    Advancements in drug development

3.2.1.2    Improved diagnostic techniques

3.2.1.3    Growing disease awareness initiatives

3.2.2    Industry pitfalls & challenges

3.2.2.1    High cost of treatment

3.2.2.2    Competition from alternative treatments

3.3    Growth potential analysis

3.4    Regulatory landscape

3.5    Future market trends

3.6    Porter's analysis

3.7    PESTEL analysis

Chapter 4   Competitive Landscape, 2023

4.1    Introduction

4.2    Company market share analysis

4.3    Company matrix analysis

4.4    Competitive analysis of major market players

4.5    Competitive positioning matrix

4.6    Strategy dashboard

Chapter 5   Market Estimates and Forecast, By Drug Type, 2021–2032 ($ Mn)

5.1    Key trends

5.2    Hypomethylating drugs

5.3    Immune therapy drugs

5.3.1    Immunomodulatory drugs

5.3.2    Immunosuppressive drugs

5.4    Antianemics drugs

5.5    Thrombopoietin receptor agonists

Chapter 6   Market Estimates and Forecast, By Route of Administration, 2021–2032 ($ Mn)

6.1    Key trends

6.2    Oral

6.3    Parenteral

Chapter 7   Market Estimates and Forecast, By Cancer Type, 2021–2032 ($ Mn)

7.1    Key trends

7.2    Refractory anemia with excess blasts (RAEB)

7.3    Refractory cytopenia with multilineage dysplasia (RCMD)

7.4    Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS)

7.5    Other cancer types

Chapter 8   Market Estimates and Forecast, By Medication, 2021–2032 ($ Mn)

8.1    Key trends

8.2    Branded

8.3    Generic

Chapter 9   Market Estimates and Forecast, By Age Group, 2021–2032 ($ Mn)

9.1    Key trends

9.2    Above 80

9.3    70-79

9.4    60-69

9.5    50-59

9.6    40-49

9.7    Below 40

Chapter 10   Market Estimates and Forecast, By End-user, 2021–2032 ($ Mn)

10.1    Key trends

10.2    Healthcare providers

10.2.1   Hospitals

10.2.2   Specialty clinics

10.3    Patients

10.4    Other end-users

Chapter 11   Market Estimates and Forecast, By Region, 2021–2032 ($ Mn)

11.1    Key trends

11.2    North America

11.2.1   U.S.

11.2.2   Canada

11.3    Europe

11.3.1   Germany

11.3.2   UK

11.3.3   France

11.3.4   Spain

11.3.5   Italy

11.3.6   Netherlands

11.3.7   Rest of Europe

11.4    Asia Pacific

11.4.1   Japan

11.4.2   China

11.4.3   India

11.4.4   Australia

11.4.5   South Korea

11.4.6   Rest of Asia Pacific

11.5    Latin America

11.5.1   Brazil

11.5.2   Mexico

11.5.3   Argentina

11.5.4   Rest of Latin America

11.6    Middle East and Africa

11.6.1   Saudi Arabia

11.6.2   South Africa

11.6.3   UAE

11.6.4   Rest of Middle East and Africa

Chapter 12   Company Profiles

12.1    Amgen Inc.

12.2    Astex Pharmaceuticals, Inc.

12.3    Bristol-Myers Squibb Company (Celgene Corporation)

12.4    Cipla Limited

12.5    Dr. Reddy's Laboratories Inc.

12.6    Hikma Pharmaceuticals PLC

12.7    Johnson & Johnson Services, Inc.

12.8    Lupin Limited

12.9    Otsuka America Pharmaceutical, Inc.

12.10    Pfizer, Inc.

12.11    Sandoz

12.12    Shilpa Medicare Limited

12.13    Sun Pharmaceutical Industries, Inc.

12.14    Takeda Pharmaceutical Company Limited

12.15    Teva Pharmaceutical Industries Ltd

Authors: Mariam Faizullabhoy, Gauri Wani
Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
    Buy now
Premium Report Details

Base Year: 2023

Companies covered: 15

Tables & Figures: 518

Countries covered: 23

Pages: 130

Download Free Sample

Top